Geographic Atrophy

Pegcetacoplan’s recent FDA approval creates an option for patients with dry AMD.

A look back on what happened in optometry during the week of April 3-April 7.

Imaging can elucidate visual prognosis and disease progression risk.

These disorders account for most of the vision loss in working-age and elderly Americans.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

Look out for at-risk patients and prepare to establish treatment protocols.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

Advancements enable better diagnosis, treatment of patients.

A decision by the FDA is expected in August 2022.

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

New detailed, longer-term findings were presented at the 2022 ARVO meeting.